MARVAX Trademark

Trademark Overview

On Monday, October 24, 2022, a trademark application was filed for MARVAX with the United States Patent and Trademark Office. The USPTO has given the MARVAX trademark a serial number of 97645573. The federal status of this trademark filing is NON-FINAL ACTION - MAILED as of Saturday, February 1, 2025. This trademark is owned by Soligenix, Inc.. The MARVAX trademark is filed in the Pharmaceutical Products category with the following description:

Vaccine preparations, namely, vaccines for immunization of humans against Marburg Virus Disease
marvax

General Information

Serial Number97645573
Word MarkMARVAX
Filing DateMonday, October 24, 2022
Status641 - NON-FINAL ACTION - MAILED
Status DateSaturday, February 1, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Goods and ServicesVaccine preparations, namely, vaccines for immunization of humans against Marburg Virus Disease

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, October 27, 2022
Primary Code005
First Use Anywhere DateMonday, April 1, 2024
First Use In Commerce DateMonday, April 1, 2024

Trademark Owner History

Party NameSoligenix, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressPrinceton, NJ 08540

Trademark Events

Event DateEvent Description
Thursday, October 27, 2022NEW APPLICATION ENTERED
Thursday, October 27, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, August 4, 2023ASSIGNED TO EXAMINER
Thursday, August 10, 2023NON-FINAL ACTION WRITTEN
Thursday, August 10, 2023NON-FINAL ACTION E-MAILED
Thursday, August 10, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, November 7, 2023APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Tuesday, November 7, 2023APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Monday, February 12, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, February 12, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, February 12, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Saturday, July 27, 2024FINAL REFUSAL WRITTEN
Saturday, July 27, 2024NOTIFICATION OF FINAL REFUSAL EMAILED
Saturday, July 27, 2024FINAL REFUSAL E-MAILED
Monday, January 27, 2025TEAS REQUEST FOR RECONSIDERATION RECEIVED
Monday, January 27, 2025EXPARTE APPEAL RECEIVED AT TTAB
Monday, January 27, 2025EX PARTE APPEAL-INSTITUTED
Tuesday, October 22, 2024APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Tuesday, October 22, 2024APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Monday, January 27, 2025TEAS AMENDMENT OF USE RECEIVED
Monday, January 27, 2025JURISDICTION RESTORED TO EXAMINING ATTORNEY
Monday, January 27, 2025AMENDMENT TO USE PROCESSING COMPLETE
Monday, January 27, 2025USE AMENDMENT FILED
Saturday, February 1, 2025NON-FINAL ACTION E-MAILED
Saturday, February 1, 2025NOTIFICATION OF NON-FINAL ACTION E-MAILED
Saturday, February 1, 2025NON-FINAL ACTION WRITTEN

Related Keywords

marvax against marburg virus disease humans immunization preparations namely vaccines vaccine